Use of albumin infusion for cirrhosis-related complications: An international position statement

Ginès, 2021, Liver cirrhosis, Lancet, 398, 1359, 10.1016/S0140-6736(21)01374-X Asrani, 2019, Burden of liver diseases in the world, J Hepatol, 70, 151, 10.1016/j.jhep.2018.09.014 2020, The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet Gastroenterol Hepatol, 5, 245, 10.1016/S2468-1253(19)30349-8 Ge, 2016, Treatment of patients with cirrhosis, N Engl J Med, 375, 767, 10.1056/NEJMra1504367 Arroyo, 2014, Human serum albumin, systemic inflammation, and cirrhosis, J Hepatol, 61, 396, 10.1016/j.jhep.2014.04.012 2018, EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis, J Hepatol, 69, 406, 10.1016/j.jhep.2018.03.024 Caraceni, 2021, The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery, J Hepatol, 75, S118, 10.1016/j.jhep.2021.01.024 Bernardi, 2018, Novel perspectives in the management of decompensated cirrhosis, Nat Rev Gastroenterol Hepatol, 15, 753, 10.1038/s41575-018-0045-2 Caraceni, 2018, Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial, Lancet, 391, 2417, 10.1016/S0140-6736(18)30840-7 Solà, 2018, Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial, J Hepatol, 69, 1250, 10.1016/j.jhep.2018.08.006 China, 2021, A randomized trial of albumin infusions in hospitalized patients with cirrhosis, N Engl J Med, 384, 808, 10.1056/NEJMoa2022166 Bai, 2019, Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization, Therap Adv Gastroenterol, 12, 10.1177/1756284819881302 Huang, 2011, Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor, Liver Int, 31, 184, 10.1111/j.1478-3231.2010.02377.x Bai, 2022, Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials, Hepatol Int, 16, 1468, 10.1007/s12072-022-10374-z Biggins, 2021, Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases, Hepatology, 74, 1014, 10.1002/hep.31884 Tarín Remohí, 2000, Costs related to inappropriate use of albumin in Spain, Ann Pharmacother, 34, 1198, 10.1345/aph.19385 Tanzi, 2003, Evaluation of the appropriate use of albumin in adult and pediatric patients, Am J Health Syst Pharm, 60, 1330, 10.1093/ajhp/60.13.1330 Yazdani, 2017, Where does the Albumin go? Human Albumin Solution usage following the implementation of a demand management programme, Transfus Med, 27, 192, 10.1111/tme.12406 Garioud, 2017, Albumin use in patients with cirrhosis in France: results of the “ALBU-LIVE” survey: a case for better EASL guidelines diffusion and/or revision, J Clin Gastroenterol, 51, 831, 10.1097/MCG.0000000000000735 Rodrigues, 2021, Intravenous albumin in patients with cirrhosis: evaluation of practice patterns and secular trends of usage in ontario 2000 to 2017, J Can Assoc Gastroenterol, 4, 179, 10.1093/jcag/gwaa027 Bajaj, 2015, Variations in albumin use in patients with cirrhosis: an AASLD members survey, Hepatology, 62, 1923, 10.1002/hep.27789 Caraceni, 2018, The use of human albumin in patients with cirrhosis: a European survey, Expert Rev Gastroenterol Hepatol, 12, 625, 10.1080/17474124.2018.1460203 Aithal, 2021, Guidelines on the management of ascites in cirrhosis, Gut, 70, 9, 10.1136/gutjnl-2020-321790 Runyon, 2009, Management of adult patients with ascites due to cirrhosis: an update, Hepatology, 49, 2087, 10.1002/hep.22853 Angeli, 2015, Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites, Gut, 64, 531, 10.1136/gutjnl-2014-308874 2016, AISF-SIMTI Position Paper: the appropriate use of albumin in patients with liver cirrhosis, Dig Liver Dis, 48, 4, 10.1016/j.dld.2015.11.008 Caraceni, 2021, AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update, Blood Transfus, 19, 9 Castro-Narro, 2022, Position statement on the use of albumin in liver cirrhosis, Ann Hepatol, 100708, 10.1016/j.aohep.2022.100708 Jünger, 2013, Consensus building on access to controlled medicines: a four-stage Delphi consensus procedure, J Pain Symptom Manage, 46, 897, 10.1016/j.jpainsymman.2013.01.014 Helmer, 1963, An experimental application of the DELPHI method to the use of experts, Manag Sci, 9, 458 Brouwers, 2016, Agree Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines, BMJ, 352, i1152, 10.1136/bmj.i1152 Esteban, 2019, Attitudes of liver and palliative care clinicians toward specialist palliative care consultation for patients with end-stage liver disease, J Palliat Med, 22, 804, 10.1089/jpm.2018.0553 Balshem, 2011, GRADE guidelines: 3. Rating the quality of evidence, J Clin Epidemiol, 64, 401, 10.1016/j.jclinepi.2010.07.015 Levitt, 2016, Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements, Int J Gen Med, 9, 229, 10.2147/IJGM.S102819 Quinlan, 2005, Albumin: biochemical properties and therapeutic potential, Hepatology, 41, 1211, 10.1002/hep.20720 Kragh-Hansen, 2002, Practical aspects of the ligand-binding and enzymatic properties of human serum albumin, Biol Pharm Bull, 25, 695, 10.1248/bpb.25.695 Dröge, 2002, Aging-related changes in the thiol/disulfide redox state: implications for the use of thiol antioxidants, Exp Gerontol, 37, 1333, 10.1016/S0531-5565(02)00175-4 Moman, 2021 Sleep, 2013, Albumin as a versatile platform for drug half-life extension, Biochim Biophys Acta, 1830, 5526, 10.1016/j.bbagen.2013.04.023 Nilsen, 2020, An intact C-terminal end of albumin is required for its long half-life in humans, Commun Biol, 3, 181, 10.1038/s42003-020-0903-7 Kerr, 1967, Use of 125-I- and 51-Cr-labeled albumin for the measurement of gastrointestinal and total albumin catabolism, J Clin Invest, 46, 2064, 10.1172/JCI105694 Hartmann, 2013, Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice, Hepatology, 58, 108, 10.1002/hep.26321 Garcia-Martinez, 2013, Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications, Hepatology, 58, 1836, 10.1002/hep.26338 Carvalho, 2018, New insights about albumin and liver disease, Ann Hepatol, 17, 547, 10.5604/01.3001.0012.0916 Baldassarre, 2021, Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications, Hepatology, 74, 2058, 10.1002/hep.31798 Dahlqvist, 2012, In-111 transferrin scintigraphy in cirrhosis with hypoalbuminemia: evidence for protein-losing enteropathy in a small group of selected cases, Scand J Gastroenterol, 47, 1247, 10.3109/00365521.2012.696682 Davcev, 1969, Protein-losing enteropathy in patients with liver cirrhosis, Digestion, 2, 17, 10.1159/000196916 Jalan, 2013, Effective albumin concentration and cirrhosis mortality: from concept to reality, J Hepatol, 59, 918, 10.1016/j.jhep.2013.08.001 Roche, 2008, The antioxidant properties of serum albumin, FEBS Lett, 582, 1783, 10.1016/j.febslet.2008.04.057 Engelmann, 2021, Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction, J Hepatol, 75, S49, 10.1016/j.jhep.2021.01.002 Manzoor, 2022 Salerno, 2007, Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis, Gut, 56, 1310 Arroyo, 1996, Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis, International Ascites Club. Hepatology, 23, 164 Simonetto, 2020, Hepatorenal syndrome: pathophysiology, diagnosis, and management, BMJ, 370, m2687, 10.1136/bmj.m2687 Angeli, 2019, News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document, J Hepatol, 71, 811, 10.1016/j.jhep.2019.07.002 Martín-Llahí, 2008, Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study, Gastroenterology, 134, 1352, 10.1053/j.gastro.2008.02.024 Boyer, 2016, Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1, Gastroenterology, 150, 1579, 10.1053/j.gastro.2016.02.026 Wong, 2021, Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome, N Engl J Med, 384, 818, 10.1056/NEJMoa2008290 Cavallin, 2015, Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial, Hepatology, 62, 567, 10.1002/hep.27709 Sanyal, 2008, A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome, Gastroenterology, 134, 1360, 10.1053/j.gastro.2008.02.014 Cavallin, 2016, Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study, Hepatology, 63, 983, 10.1002/hep.28396 Saif, 2018, Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study, Indian J Gastroenterol, 37, 424, 10.1007/s12664-018-0876-3 Sharma, 2008, An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response, Am J Gastroenterol, 103, 1689, 10.1111/j.1572-0241.2008.01828.x Pomier-Layrargues, 2003, Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study, Hepatology, 38, 238, 10.1053/jhep.2003.50276 Alessandria, 2007, Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study, J Hepatol, 47, 499, 10.1016/j.jhep.2007.04.010 Ghosh, 2013, Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study, Liver Int, 33, 1187, 10.1111/liv.12179 Ortega, 2002, Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study, Hepatology, 36, 941 Salerno, 2015, Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis, BMC Gastroenterol, 15, 167, 10.1186/s12876-015-0389-9 Quintero, 1985, Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites, Lancet, 1, 611, 10.1016/S0140-6736(85)92147-6 Ginés, 1987, Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study, Gastroenterology, 93, 234, 10.1016/0016-5085(87)91007-9 Ruiz-del-Arbol, 1997, Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis, Gastroenterology, 113, 579, 10.1053/gast.1997.v113.pm9247479 Ginès, 1988, Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis, Gastroenterology, 94, 1493, 10.1016/0016-5085(88)90691-9 Ginès, 1996, Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis, Gastroenterology, 111, 1002, 10.1016/S0016-5085(96)70068-9 Solà, 1994, Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study, J Hepatol, 20, 282, 10.1016/S0168-8278(05)80070-4 Bernardi, 2012, Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials, Hepatology, 55, 1172, 10.1002/hep.24786 Simonetti, 2019, Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis, Cochrane Database Syst Rev, 6, CD004039 Shrestha, 2021, Safety and efficacy of human serum albumin treatment in patients with cirrhotic ascites undergoing paracentesis: a systematic review and meta-analysis, Ann Hepatol, 26, 100547, 10.1016/j.aohep.2021.100547 Moore, 2006, Guidelines on the management of ascites in cirrhosis, Gut, 55, vi1 Peltekian, 1997, Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites, Am J Gastroenterol, 92, 394 Arora, 2020, Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure, Hepatology, 72, 1043, 10.1002/hep.31071 Fleming, 2010, The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study, Aliment Pharmacol Ther, 32, 1343, 10.1111/j.1365-2036.2010.04473.x Bernardi, 2015, Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis, J Hepatol, 63, 1272, 10.1016/j.jhep.2015.07.004 Schrier, 1988, Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis, Hepatology, 8, 1151, 10.1002/hep.1840080532 Wilkinson, 1962, The effect of repeated albumin infusions in patients with cirrhosis, Lancet, 2, 1125, 10.1016/S0140-6736(62)90895-4 Gentilini, 1999, Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial, J Hepatol, 30, 639, 10.1016/S0168-8278(99)80194-9 Romanelli, 2006, Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial, World J Gastroenterol, 12, 1403, 10.3748/wjg.v12.i9.1403 Sandi, 2021, Long-term albumin administration in patients with cirrhosis and ascites: a meta-analysis of randomized controlled trials, J Gastroenterol Hepatol, 36, 609, 10.1111/jgh.15253 Di Pascoli, 2019, Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites, Liver Int, 39, 98, 10.1111/liv.13968 Caraceni, 2021, On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites, J Hepatol, 74, 340, 10.1016/j.jhep.2020.08.021 Fernández, 2012, Management of bacterial infections in cirrhosis, J Hepatol, 56, S1, 10.1016/S0168-8278(12)60002-6 Fernández, 2012, Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study, Hepatology, 55, 1551, 10.1002/hep.25532 Fernández, 2002, Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis, Hepatology, 35, 140, 10.1053/jhep.2002.30082 Arvaniti, 2010, Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis, Gastroenterology, 139, 1246, 10.1053/j.gastro.2010.06.019 Jalan, 2014, Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013, J Hepatol, 60, 1310, 10.1016/j.jhep.2014.01.024 Piano, 2016, The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial, Hepatology, 63, 1299, 10.1002/hep.27941 Dever, 2015, Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention, Aliment Pharmacol Ther, 41, 1116, 10.1111/apt.13172 Sort, 1999, Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis, N Engl J Med, 341, 403, 10.1056/NEJM199908053410603 Chen, 2009, Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis, Scand J Gastroenterol, 44, 619, 10.1080/00365520902719273 Fernández, 2005, A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis, Hepatology, 42, 627, 10.1002/hep.20829 Terra, 2005, Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score, Gastroenterology, 129, 1944, 10.1053/j.gastro.2005.09.024 Guevara, 2012, Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study, J Hepatol, 57, 759, 10.1016/j.jhep.2012.06.013 Thévenot, 2015, Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial, J Hepatol, 62, 822, 10.1016/j.jhep.2014.11.017 Fernández, 2020, Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis, Clin Gastroenterol Hepatol, 18, 963, 10.1016/j.cgh.2019.07.055 Fernández, 2019, Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis, Gastroenterology, 157, 149, 10.1053/j.gastro.2019.03.021 Wong, 2020, Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: a systematic review and meta-analysis, Dig Liver Dis, 52, 1137, 10.1016/j.dld.2020.05.047 Wijdicks, 2016, Hepatic encephalopathy, N Engl J Med, 375, 1660, 10.1056/NEJMra1600561 2022, EASL Clinical Practice Guidelines on the management of hepatic encephalopathy, J Hepatol, 77, 807, 10.1016/j.jhep.2022.06.001 2014, European association for the study of the liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European association for the study of the liver and the American association for the study of liver diseases, J Hepatol, 61, 642, 10.1016/j.jhep.2014.05.042 Brusilow, 2010, Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy, Neurotherapeutics, 7, 452, 10.1016/j.nurt.2010.05.015 González-Usano, 2013, Hyperammonemia alters the modulation by different neurosteroids of the glutamate-nitric oxide-cyclic GMP pathway through NMDA- GABAA - or sigma receptors in cerebellum in vivo, J Neurochem, 125, 133, 10.1111/jnc.12119 Gluud, 2016, Nonabsorbable disaccharides for hepatic encephalopathy: a systematic review and meta-analysis, Hepatology, 64, 908, 10.1002/hep.28598 Bass, 2010, Rifaximin treatment in hepatic encephalopathy, N Engl J Med, 362, 1071, 10.1056/NEJMoa0907893 Kircheis, 1997, Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study, Hepatology, 25, 1351, 10.1002/hep.510250609 Bosoi, 2013, Oxidative stress: a systemic factor implicated in the pathogenesis of hepatic encephalopathy, Metab Brain Dis, 28, 175, 10.1007/s11011-012-9351-5 Jain, 2012, Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy, Dig Liver Dis, 44, 1027, 10.1016/j.dld.2012.07.002 Simón-Talero, 2013, Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study, J Hepatol, 59, 1184, 10.1016/j.jhep.2013.07.020 Sharma, 2017, Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy, J Gastroenterol Hepatol, 32, 1234, 10.1111/jgh.13666 Bai, 2019, Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis, Aging (Albany NY), 11, 8502, 10.18632/aging.102335 Fagan, 2023, A double-blind randomized placebo-controlled trial of albumin in patients with hepatic encephalopathy: HEAL study, J Hepatol, 78, 312, 10.1016/j.jhep.2022.09.009 Teh, 2021, Efficacy and safety of albumin infusion for overt hepatic encephalopathy: a systematic review and meta-analysis, Dig Liver Dis, 53, 817, 10.1016/j.dld.2021.04.030 Is, 2021, Albumin in the management of hepatic encephalopathy: a systematic review and meta-analysis, Ann Hepatol, 26 Wong, 2023, Albumin therapy for hepatic encephalopathy: current evidence and controversies, Metab Brain Dis, 38, 1759, 10.1007/s11011-022-01002-8 Angeli, 2006, Hyponatremia in cirrhosis: results of a patient population survey, Hepatology, 44, 1535, 10.1002/hep.21412 Attar, 2019, Approach to hyponatremia in cirrhosis, Clin Liver Dis (Hoboken), 13, 98, 10.1002/cld.790 Kim, 2008, Hyponatremia and mortality among patients on the liver-transplant waiting list, N Engl J Med, 359, 1018, 10.1056/NEJMoa0801209 Borroni, 2000, Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients, Dig Liver Dis, 32, 605, 10.1016/S1590-8658(00)80844-0 Alukal, 2020, Hyponatremia in cirrhosis: an update, Am J Gastroenterol, 115, 1775, 10.14309/ajg.0000000000000786 Bajaj, 2018, The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis, Am J Gastroenterol, 113, 1339, 10.1038/s41395-018-0119-3 China, 2021, Targeted albumin therapy does not improve short-term outcome in hyponatremic patients hospitalized with complications of cirrhosis: data from the ATTIRE trial, Am J Gastroenterol, 116, 2292, 10.14309/ajg.0000000000001488 Zaccherini, 2023, Correction and prevention of hyponatremia in patients with cirrhosis and ascites - post hoc analysis of the ANSWER study database, Am J Gastroenterol, 118, 168, 10.14309/ajg.0000000000001995 Bai, 2022, Use of human albumin administration for the prevention and treatment of hyponatremia in patients with liver cirrhosis: a systematic review and meta-analysis, J Clin Med, 11, 5928, 10.3390/jcm11195928 Rogal, 2022, AASLD Practice Guidance: palliative care and symptom-based management in decompensated cirrhosis, Hepatology, 76, 819, 10.1002/hep.32378 Angeli, 1996, Cirrhosis and muscle cramps: evidence of a causal relationship, Hepatology, 23, 264, 10.1002/hep.510230211 Elfert, 2016, Randomized placebo-controlled study of baclofen in the treatment of muscle cramps in patients with liver cirrhosis, Eur J Gastroenterol Hepatol, 28, 1280, 10.1097/MEG.0000000000000714 Lee, 1991, A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps, J Hepatol, 12, 236, 10.1016/0168-8278(91)90944-7 Foreman, 2003, Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey, Chest, 124, 1016, 10.1378/chest.124.3.1016 Gotts, 2016, Sepsis: pathophysiology and clinical management, BMJ, 353, i1585, 10.1136/bmj.i1585 Gustot, 2009, Severe sepsis in cirrhosis, Hepatology, 50, 2022, 10.1002/hep.23264 Plessier, 2003, Coagulation disorders in patients with cirrhosis and severe sepsis, Liver Int, 23, 440, 10.1111/j.1478-3231.2003.00870.x Simonetto, 2019, Management of sepsis in patients with cirrhosis: current evidence and practical approach, Hepatology, 70, 418, 10.1002/hep.30412 Sauneuf, 2013, Increased survival of cirrhotic patients with septic shock, Crit Care, 17, R78, 10.1186/cc12687 Philips, 2021, Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial, Hepatol Int, 15, 983, 10.1007/s12072-021-10164-z Maiwall, 2022, A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial], J Hepatol, 77, 670, 10.1016/j.jhep.2022.03.043 Shasthry, 2017, Changes in cardiac output and incidence of volume overload in cirrhotics receiving 20% albumin infusion, Liver Int, 37, 1167, 10.1111/liv.13375 Umgelter, 2008, Haemodynamic effects of plasma-expansion with hyperoncotic albumin in cirrhotic patients with renal failure: a prospective interventional study, BMC Gastroenterol, 8, 39, 10.1186/1471-230X-8-39 Bai, 2021, Human albumin infusion strategy in liver cirrhosis: liberal or restrictive?, Ann Transl Med, 9, 1114, 10.21037/atm-21-2136 Allegretti, 2022, Respiratory events with terlipressin and albumin in hepatorenal syndrome: a review and clinical guidance, Liver Int, 42, 2124, 10.1111/liv.15367 Fujita, 2007, Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting, J Anesth, 21, 396, 10.1007/s00540-007-0512-3 Moreno Lozano, 2019, Human serum albumin induced anaphylaxis in a patient with good tolerance to human plasma, J Investig Allergol Clin Immunol, 29, 51, 10.18176/jiaci.0325 Ring, 1979, Anaphylactoid reactions to infusions of plasma protein and human serum albumin. Role of aggregated proteins and of stabilizers added during production, Clin Allergy, 9, 89, 10.1111/j.1365-2222.1979.tb01527.x Stafford, 1988, Anaphylaxis to human serum albumin, Ann Allergy, 61, 85 Dengler, 1989, Chemical and immunochemical characterization of polymers of aggregates in preparations of human serum albumin, Infusionstherapie, 16, 160 Jensen, 1994, Identification and removal of polymer- and aggregate-forming proteins in human plasma albumin preparations, Vox Sang, 67, 125, 10.1111/j.1423-0410.1994.tb01646.x Faloon, 1949, An evaluation of human serum albumin in the treatment of cirrhosis of the liver, J Clin Invest, 28, 583, 10.1172/JCI102108 Kunkel, 1948, The use of concentrated human serum albumin in the treatment of cirrhosis of the liver, J Clin Invest, 27, 305, 10.1172/JCI101959 Wang, 2020, The impact of albumin infusion on the risk of rebleeding and in-hospital mortality in cirrhotic patients admitted for acute gastrointestinal bleeding: a retrospective study of a single institute, BMC Gastroenterol, 20, 198, 10.1186/s12876-020-01337-5